These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6681597)

  • 1. Release of a 6-oxoprostaglandin E1-like substance from human platelets.
    Lofts FJ; Moore PK
    Clin Sci (Lond); 1983 Jan; 64(1):63-8. PubMed ID: 6681597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catabolism of 6 keto PGE1: biological activation by the rat kidney in vitro.
    Moore PK; Griffiths RJ; Gaffen ZA
    Eur J Pharmacol; 1983 Jul; 91(2-3):311-5. PubMed ID: 6684573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism?
    Mikhailidis DP; Mikhailidis AM; Woollard ML; Dandona P
    Clin Sci (Lond); 1982 Feb; 62(2):177-81. PubMed ID: 7032807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung.
    Berry CN; Griffiths RJ; Hoult JR; Moore PK; Taylor GW
    Br J Pharmacol; 1986 Feb; 87(2):327-35. PubMed ID: 3955304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
    Wilsoncroft PS; Lofts FJ; Griffiths RJ; Moore PK
    J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1.
    Moore PK; Griffiths RJ; Lofts FJ
    Biochem Pharmacol; 1983 Sep; 32(18):2813-7. PubMed ID: 6414481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of biologically active substances from non-aggregating human platelets.
    Lofts FJ; Moore PK
    Eur J Pharmacol; 1982 May; 80(2-3):203-7. PubMed ID: 7106175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-Keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells.
    Oliva D; Bernini F; Corsini A; Nicosia S
    Biochem Pharmacol; 1984 Dec; 33(23):3755-8. PubMed ID: 6391491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of prostaglandin I2 in human blood.
    Pifer DD; Cagen LM; Chesney CM
    Prostaglandins; 1981 Feb; 21(2):165-75. PubMed ID: 7012932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic AMP induces synthesis of prostaglandin E1 in platelets.
    Dayal V; Colman RW; Prakash O; Bose AK; Sinha AK
    Biochim Biophys Acta; 1983 Sep; 759(3):129-36. PubMed ID: 6309248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: 6 keto-prostaglandin-E1.
    Moore PK; Griffiths RJ
    Prostaglandins; 1983 Oct; 26(4):509-17. PubMed ID: 6361908
    [No Abstract]   [Full Text] [Related]  

  • 15. Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin.
    McGiff JC; Spokas EG; Wong PY
    Br J Pharmacol; 1982 Jan; 75(1):137-44. PubMed ID: 7042021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P; Kaliman J; Sinzinger H
    Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of in vitro and in vivo exposure to insulin upon prostaglandin E1 stimulation of platelet adenylate cyclase activity in healthy subjects.
    Jap TS; Kwok CF; Wong MC; Chiang H
    Diabetes Res; 1994; 27(1):39-46. PubMed ID: 7648795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activities of 6-keto-prostaglandin E1.
    Lewis R; Schölkens BA; Beck G
    Prostaglandins Leukot Med; 1984 Dec; 16(3):303-24. PubMed ID: 6098901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
    Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.